Associated Papers
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
Heymach JV et al.
Expert Review of Anticancer Therapy, 2026
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
Dey P et al.
Oncogene, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026
Tumor-normal sequencing reveals novel TP53 germline and clinically actionable somatic mutations in Nigerian breast cancer patients.
Onyia AF et al.
Cancer Genetics, 2026
The GigaAssay: A combined high throughput and highly accurate platform for variant classification.
Giacoletto CJ et al.
New Biotechnology, 2025
Clinical characteristics and treatment of EGFR exon 19 L747 mutation in advanced NSCLC: a retrospective study.
Yang Y et al.
Bmc Cancer, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Comparative Performance of a Targeted Next-Generation Sequencing Assay Against Multiplexed Digital PCR Assays in Detecting ERBB2, ESR1, and PIK3CA Mutations in Plasma Circulating Cell-Free DNA from Liquid Biopsies.
Corné J et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Paired tumor-normal sequencing provides insights into the CDKN2A-associated tumor spectrum.
Breen KE et al.
Npj Precision Oncology, 2025
High-throughput characterization of 5886 HER2 variants identifies 112 new in cellulo gain-of-function mutations.
Giacoletto CJ et al.
Genomics, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer.
Vandekerkhove G et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review.
Abujamous L et al.
The Oncologist, 2025
HER2 alterations across solid tumors: implications for comprehensive testing.
Ismail A et al.
The Oncologist, 2025
Molecular Landscape, Genomic Shift, and Prediction in the Neoadjuvant Setting of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Pons L et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
HER2 mutation profiling in mucinous ovarian carcinoma: Inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach.
Shen HP et al.
Taiwanese Journal of Obstetrics & Gynecology, 2025
Whole-miRNome sequencing: a panel for the targeted sequencing of all human miRNA genes.
Galka-Marciniak P et al.
Nucleic Acids Research, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single centre analysis on site.
Bontoux C et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2025
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors.
Egebjerg K et al.
Bmc Cancer, 2025
Genetic landscapes of breast tumors by next-generation sequencing with focus on less common types and genotype-phenotype correlations.
Hoda RS et al.
Human Pathology, 2025
HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.
Cheng X et al.
Biorxiv : the Preprint Server for Biology, 2025
[Characteristics of KRAS and HER-family gene mutations in ampullary cancer].
Zeng LL et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2025
Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use.
Meintani A et al.
International Journal of Molecular Sciences, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors.
Chan HT et al.
Clinical Chemistry, 2025
Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.
Kim SC et al.
Breast Cancer Research : Bcr, 2025
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer.
Berg T et al.
Neoplasia (new York, N.y.), 2025
Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
Bossé Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
Revisiting variation in the somatic mutation landscape of non-small cell lung cancer.
Pathak V et al.
Hgg Advances, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.
Liu D et al.
Cancer Research Communications, 2025
ERBB2 Comprehensive Profiling and Prognostication in Stage III Colon Cancer: Findings From PETACC8 and IDEA-France Cohorts.
Pilati C et al.
Gastroenterology, 2025
Whole exome sequencing of multi-regions reveals tumor heterogeneity in Opisthorchis viverrini-associated cholangiocarcinoma.
Sitthirak S et al.
Scientific Reports, 2025
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation.
Giacoletto CJ et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis.
Xiang Y et al.
Current Oncology (toronto, Ont.), 2025
ERBB2/ERBB3-mutated S100/SOX10-positive uterine sarcoma: something new.
Shi WJ et al.
Virchows Archiv : an International Journal of Pathology, 2025
CDK4 gene copy number increase and concurrent genetic changes in acral melanoma of a Chinese cohort.
Yang L et al.
Pathology, 2025
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer.
DiPeri TP et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025